100 results about "Serum glutamate pyruvate transaminase" patented technology

The invention provides compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to normalize the level of serum glutamate-pyruvate Transaminase (GPT), or reduce serum HBsAg levels in a subject, said ability resulting from their having been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength. Also provided are methods of making and using these compositions.

The invention discloses a Chinese date leaf extractive and an application thereof in preparation of a medicament or health food for preventing and treating liver injury. The way that macroporous resin is coupled with polyamide resin and then a fine Chinese date leaf extractive is prepared through a preparative liquid phase is firstly adopted; compared with the traditional separation and purification method, the way has the advantages that the separation efficiency is higher, the active component obtained through separation is higher in content, strong in biological activity and high in safety. Experiment researches show that the Chinese date leaf extractive can be used for remarkably reducing the activities of ALT (Alanine Transaminase) and AST (Aspartate Transaminase) in serum of a model mouse with liver injury caused by CCl4, D-GalN and ethanol and the content of MDA (Methyl Di Aldehyde) in liver tissues and enhancing the activity of SOD (Superoxide Dismutase) of the liver and has favorable preventing and treating effects. Therefore, Chinese date leaves and the Chinese date leaf extractive are expected to be developed into a new-generation safe and effective medicament or health food for preventing and treating liver injury, and meanwhile, an approach is also provided for turning the waste Chinese date leaf resource into the things of value and comprehensively utilizing a date tree resource.

The invention discloses refined glossy privet fruit total glycosides capable of preventing and treating liver injury and a preparation method thereof. The preparation method is characterized in that the chemical compositions and pharmacological activity of the glossy privet fruit are researched and selected systematically; and the experiment results show that the selected refined glossy privet fruit total glycosides can obviously reduce serum ALT (Alanine Transaminase) and AST (Aspartate Aminotransferase) activities of a CCl4-induced liver injury model mice and the MDA (Methyl Di Aldehyde) content in the hepatic tissue of an alcohol-induced liver injury model mice and improve the GSH (Glutathione) activity of the liver, and also show that the refined glossy privet fruit total glycosides provided by the invention not only can obviously protect the liver from chemical liver injury and long-term drinking induced liver injury and can be developed into novel medicines or health products for preventing liver injury.

The invention discloses a dry chemical quantitative test strip with interference removal, comprising a substrate, a sampling region which is provided with a fixed interference removing reagent and arranged on the substrate, and a promoter region which is provided with a fixed test reaction promoter and a fixed signal supplying reagent and is arranged on the substrate, wherein, the sampling region and the promoter region are distributed on the test strip under the conditions that: the sampling region keeps non-contact with the promoter region in normal state, and the sampling region contacts with the promoter region in test state. The test method comprises the following steps: adding a sample liquid to the tested in the sampling region, redissolving the substance fixed on the sampling region in the sample liquid to the tested, carrying out reaction for removing interference; then contacting the promoter region with the sampling region, redissolving the substance fixed on the promoter region, and carrying out reaction for test; carrying out signal reaction on the reaction product, and according to the tested signal value, calculating the content of biological enzyme to be tested. The test method has the advantages of simple operation, low test cost, accurate test result, and high test precision, and can be concretely applied for the quantitative test of alanine transaminase or aspartate transaminase.

The invention provides a compound microorganism beverage. The compound microorganism beverage has the advantages that the content of compound microorganisms is high, the activity is high, the stability is high, the action effect is quick, any side effect is avoided, the storage time is long, and the obvious liver protecting and hangover alleviating effects are realized. The compound microorganismbeverage is prepared by mixing the following raw materials in parts by weight: 30 to 40 parts of bacillus subtilis fermenting solution, 30 to 40 parts of thiocapsa roseopersicina fermenting solution,and 30 to 40 parts of rhizopus oryzae fermenting solution. The compound microorganism beverage has the advantages that the selected bacteria are screened by the hangover alleviating and ethyl alcoholretention rate test; higher ethyl alcohol retention rate can inhibit the absorbing of ethyl alcohol by gastrointestinal tract, and accelerate the metabolism of ethyl alcohol in stomach, and then the concentration of ethyl alcohol in blood is reduced; the compound microorganism beverage contains rich polyglutamic acid, polypeptide, polysaccharide and probiotics, so that the levels of ALT (alanine transaminase) and AST (aspartate transaminase) in serum are effectively reduced, the alcoholic liver injury is prevented and treated, and the liver injury is reduced by improving the anti-oxidizing ability of liver.

The invention discloses a co-culture system for liver cells and Kupffer cells and application thereof. The co-culture system is characterized in that in a Millicell double-layer culture room, 1-100 ng/mL LPS (lipopolysaccharides) is added into a culture medium, the Kuffer cells are cultured in the upper layer of the Millicell double-layer culture room, and the liver cells are cultured in the lower layer of the Millicell double-layer culture room; and half of the fresh culture medium is replaced every other day so as to keep the concentration of the LPS. The co-culture system for liver cells and Kupffer cells provided by the invention has the advantages that the Kupffer cells continuously secrete inflammatory cell factors (such as TNF-alpha) in vitro after being stimulated by the LPS; the liver cells can generate a great number of enzymes, such as AST (aspartate aminotransferase), ALT (alanine transaminase) and GGT (gamma-glutamyl transpeptidase) in the environment so as to stimulate the liver injury based on immunoreaction caused by the immune/inflammation response after the liver tissue undergoes virus infection in vivo; and moreover, the co-culture system is used for screening medicaments resisting immune liver injury according to the influence of the medicaments on the secretion amount of immune factors and the enzymatic activity.

The invention provides edible vinegar/vinegar paste prepared by utilizing vintage wine yeast micropopulation. The edible vinegar/vinegar paste is brewed by micropopulation of vintage wine yeast, free amino acid total content is 0.403-0.835mg/g, arginine content should be greater than 0.034mg/g, valine content is greater than 0.033mg/g, and aspartic acid content is greater than 0.026mg/g. The edible vinegar/vinegar paste can be used for preparing drug or healthcare products for lowering alanine transaminase (ALT), aspartate transaminase (AST), total cholesterol (TC) triglyceride (TG) and uric acid (UA) and protecting liver. The invention further provides a method of utilizing the vintage wine yeast micropopulation to prepare the edible vinegar/vinegar paste.

The invention discloses a water-soluble fullerene structure for preparing a medicine for treating fatty liver, and discloses a pharmaceutical composition and a method for treating fatty liver. Activeingredients for treating fatty liver are water-soluble fullerene, water-soluble inlaid metal fullerene, composition of the water-soluble fullerene and the water-soluble inlaid metal fullerene, and pharmaceuitical ester of above three and pharmaceutical salt of the three. The active ingredient water-soluble fullerene structure can reduce fatty vesicles in the liver, lower blood lipids, and obviously improve liver function, so that the content of alanine aminotransferase and aspartate aminotransferase tends to be normal, and the effect of treating fatty liver is highly effective. The active ingredient water-soluble fullerene structure can also regulate the level of redox in the liver.

A novel alanine transaminase gene (ALT2) is isolated from human tissue. ALT2 specific polynucleotides, polypeptides, and antibodies are described. ALT2 is expressed predominately in liver, kidney, brain, muscle, and adipose tissue. ALT2 can be used to diagnose injury and diseases involving tissues expressing ALT2.

The invention relates to the technical field of biology and in particular relates to a method for constructing a hepatitis B virus (HBV) infected mouse model and application of the HBV infected mouse model. The invention provides a method for constructing a high-ALT (alanine transaminase) HBV infected mouse model. The method for constructing the HBV infected mouse model comprises the step of medicating HBV genome DNA plasmid to a Tlr2 gene-deficient mouse, so that the HBV infected mouse model is constructed. The mouse model provided by the invention is relatively simple to construct, relatively easy in technological means and low in construction cost; besides, the adopted HBV plasmid vector is non-toxic, can not induce immune response of the mouse and also can avoid serious immunodeficiency in a chimera mouse model, and the obtained HBV infected model has higher blood serum ALT level and obvious liver inflammation expression.

The invention discloses lactobacillus paracasei capable of relieving alcoholic intestinal injury and an application of the lactobacillus paracasei capable of relieving alcoholic intestinal injury, andbelongs to the technical field of microorganisms and medicines, The invention provides a medicine capable of preventing and/or treating alcoholic intestinal injury or alcoholic liver injury. Effective components of the medicine are lactobacillus paracasei CCFM1120, and the lactobacillus paracasei CCFM1120 can effectively relieve the alcoholic intestinal injury and the alcoholic liver injury. Thelactobacillus paracasei has the specific effects that the mRNA expression level of intestine tight junction proteins of alcohol modeled mice can be notably increased, the content of endotoxin in serumof the alcohol modeled mice can be notably reduced, the activity of alanine aminotransferase and aspartate aminotransferase in the serum of the alcohol modeled mice can be notably reduced, the oxidation stress level of the liver of the alcohol modeled mice can be notably reduced, and the pathology damage of liver tissue of the alcohol modeled mice can be notably improved.

The invention discloses application of adenosine and derivatives thereof in prevention and treatment of medicament-induced liver injury, relating to application of adenosine and derivatives thereof such as adenosine monophosphate, adenosine diphosphate and adenosine triphosphate in protection of acetaminophen-induced liver injury. A mouse model adopted in the application is an acetaminophen-induced mouse acute hepatic failure model, the dosage of the adenosine or derivatives thereof is 0.1 to 5mmol/kg, and the adenosine and derivatives thereof can reduce the activities of aspartate aminotransferase (AST) and alanine transaminase (ALT) in the medicament-induced liver injury, reduce the substantial cell necrosis area and improve the glutathione level so as to prevent and treat the acetaminophen-induced liver injury caused by liver toxic medicaments. Animal experiments prove that the adenosine and derivatives thereof have a significant effect on preventing and treating the medicament-induced liver injury, so the adenosine and derivatives thereof can be used for the preventing and treating processes of the medicament-induced liver injury, and a new method and means are provided for clinically treating the medicament-induced liver injury.

The invention relates to a photochemical-transmission photometry method detection card capable of automatically filtering red blood cells and simultaneously detecting three indexes of a liver function: alanine transaminase (ALT), aspartate aminotransferase (AST) and glutamyl transpeptidase (gamma-GT or GGT) and belongs to the dry chemical analysis technology field. An automatic blood filtering dryphotochemical method microchannel liver function detection card is formed by five layers of film structures, and the structures contain holes and microchannels for loading, detecting and inlaying a blood filtering film. During a detection process, whole blood is filtered through the blood filtering film, and filtered serum enters into a detection hole through the microchannels. A detection item in a sample is quantitatively analyzed by testing the intensity changes of transmission light of the detection hole. By using the photochemical method microchannel liver function multi-item detection card, automatic blood filtering can be realized, the serum does not need to be separated, and the whole blood can be used to quickly and sensitively detect multiple biochemical indexes. A test result of the invention is linear, CV and other indexes can satisfy a clinical test requirement.

The invention discloses a method for quantitatively detecting alanine transaminase in a solution based on a copper nanocluster fluorescent probe, wherein a copper nanocluster with glutathione as a protective agent is used as a fluorescent probe, and the content of alanine transaminase in the solution is specifically detected through a fluorescence "off-on" mode. The label-free, highly sensitive and selective detection of alanine transaminase is achieved by adopting the fluorescence "off-on" mode. The method is simple and rapid, the specific detection of alanine transaminase can be realized, the detection linear range is wide, and the detection limit is low. The method in the invention has good detection sensitivity and selectivity and has good application prospects in disease detection, clinical application and other aspects.

The invention discloses a test card for the liver function and a preparation method thereof. The test card comprises an upper shell, a lower shell, a sample adding hole formed in the upper shell, an alanine transaminase detecting unit, a total bilirubin detecting unit and a glutamic oxalacetic transaminase detecting unit, wherein the alanine transaminase detecting unit, the total bilirubin detecting unit and the glutamic oxalacetic transaminase detecting unit are disposed between the upper shell and the lower shell. The alanine transaminase detecting unit, a total bilirubin detecting unit anda glutamic oxalacetic transaminase detecting unit comprise a bottom plate disposed at the upper end of the lower shell, lower shell detecting holes formed in the lower shell, bottom plate detecting holes formed in the bottom plate, a diffusion film disposed at the lower end of the upper shell and connected to the bottom plate, a whole blood separation layer disposed under the diffusion film and areaction layer disposed between the whole blood separation layer and the bottom plate detecting holes. The test card is matched with a dry biochemical analyzer for use, the operation is simple, the content of alanine transaminase, total bilirubin and glutamic oxalacetic transaminase can be detected rapidly and simultaneously without the need of a professional, and the detecting results are well matched with hospital detecting results.

The present invention relates to a pleurotus citrinopileatus germ bran polysaccharide and an extraction process and an application thereof. The pleurotus citrinopileatus germ bran polysaccharide extracted by the extraction process under specific conditions by taking pleurotus citrinopileatus germ bran as a raw material is not only high in extraction rate, but also excellent in reducing the elevation of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase caused by acute liver injury, as well as improving drugs for albumin decrease caused by acute liver injury, and increasing the superoxide dismutase activity, catalase activity, lipid peroxide content, and/or malondialdehyde decreased biological activity caused by acute liver injury.

The invention provides application of cistanche total glycosides and echinacoside in preparation of medicines for preventing and treating alcoholic liver injury with intestinal injury and regulating intestinal flora. Pharmacological experiment results show that in an alcoholic liver injury mouse model, the cistanche total glycosides and echinacoside can relieve mouse liver tissue morphological injury, reduce mouse liver lipid deposition, reduce the content of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse liver, relieve oxidative injury of mouse liver, and reduce damage of harmful substances such as endotoxin and the like to liver; and meanwhile, the mouse small intestine tissue form damage can be relieved, the intestinal wall villus integrity is improved, and the intestinal flora disorder is regulated. Therefore, the invention has the prospect of being developed into a medicine capable of simultaneously protecting the alcoholic liver injury and the alcoholic intestinal injury, and has important clinical significance and commercial value.

The invention discloses application of a chitosan oligosaccharide (COSM) with the molecular weight not higher than 3000 to preparing a drug-induced liver injury protecting and treating composition, particularly a composition for protecting and treating acetaminophen-induced liver injury. The invention also discloses a drug-induced liver injury protecting and treating method. The drug-induced liverinjury protecting and treating method comprises providing a liver injury patient with an effective quantity of the COSM. Experiments prove that the COSM can adjust acetaminophen-induced abnormity ofliver function biochemical indexes, significantly reduce abnormal rise of ALT (alanine transaminase) and AST (aspartate transaminase) in mice serum, improve acetaminophen-induced liver injury, improvethe content of a detoxicant of glutathione (GSH) in acetaminophen-induced liver injury-affected liver tissues, enhance the oxidation resistance of acetaminophen-induced oxidative injury-affected liver and reduce the content of malondialdehyde (MDA) of acetaminophen-induced liver oxidative injury. The COSM is expected to be developed and applied to treating liver injury caused by clinical treatment drugs and provide a better choice for patients.

The invention discloses an application of methane injection in preparation of medicaments for treating ischemia-reperfusion injury, which comprises a preparation method of the methane injection. Animal experiments are performed on the methane injection, and the results prove that the methane injection can be used for obviously reducing the level of alanine transaminase, reducing liver injury and reducing hepatocyte apoptosis against a rat model with liver ischemia-reperfusion injury, so that the methane injection can be used for treating the liver ischemia-reperfusion injury. Thus, the methane injection disclosed by the invention can be used for preparing the medicaments for treating the ischemia-reperfusion injury.

The invention relates to the use of Fraxinellone as medicament for treating hepatic diseases, wherein the Fraxinellone is separated from the velamen of Dictamnus dasycorpus Turcz, the Fraxinellone can substantially improve acute hepatic injury in mouse induced with CCl4, D-galactosamine and lipopolysaccharide, in addition, the Fraxinellone can substantially inhibit the release of glutamate-pyruvate transaminase in CCl4 induced mouse primary culture hepatocytes injuries, thus can be used as a novel medicament for treating hepatic diseases.

The present invention relates to the measuring method of the content of ammonia (ammonia ion) using enzyme cycle amplification method, enzyme colorimetric method and enzyme-linked method technology, the composition and the composition of reagent, the technical principle of its measuring is based on glutamic acid oxidase, glutamic acid oxidase, glutamic acid The serial catalytic reactions of alanine aminotransferase and alanine dehydrogenase are completed, and the invention also relates to an ammonia (ammonia ion) diagnosis/measurement kit. The assay method of the present invention has high sensitivity and small error, so the assay method and kit of the present invention can be widely used in clinical medicine/food inspection.

The invention provides application of valeriana jatamansi jones or extracts thereof in the preparation of a medicine for lowering the fat and protecting the liver. The invention also provides a pharmaceutical composition for lowering the fat and protecting the liver. Animal experiments prove that the valeriana jatamansi jones or the extracts thereof has/have the functions of reducing blood fat and serum AST (aspartate transaminase), ALT (alanine transaminase), and can be used for the treatment of hyperlipidemia with definite efficacy thereby providing a new choice the clinic.

The invention discloses a liver-protecting health-care molecular wine containing total flavonoids. Traditional processing or soaking methods of traditional Chinese medicine prescriptions are broken through, medicinal and edible homologous plants containing rich flavonoids are enriched and extracted by an enzymatic extraction process to obtain a total flavonoid crude extract fermentation broth, then total flavonoid powder is obtained, and the total flavonoid powder and baijiu are prepared in proportion to obtain molecular wine. The molecular wine has the auxiliary treatment or prevention effect on alcoholic liver injury, can reduce the content of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in liver tissue supernatant, and increase the total antioxidant capacity (T-AOC) in the liver tissue supernatant, so that the livers are prevented from injuries or the injuries caused by ethyl alcohol are decreased when people enjoy drinking pleasure. Compared with traditionalbrewed wine, the wine has a light color, no extraneous odor and no precipitation impurities, can improve the alcohol resisting ability and alcohol tolerance of drinkers through long-term drinking.

The invention discloses an application of formononetin to treatment of nonalcoholic fatty liver disease. An in vitro and an in vitro cell model are adopted, formononetin is used for treating animals,and the improvement effect of the formononetin on metabolic syndromes of nonalcoholic fatty liver, obesity, insulin resistance, lipid disorders and the like can be observed. Experiment proves that theformononetin can notably reduce weight, liver weight/body mass indexes, liver triglyceride(TG), liver lipidoses, liver function damage criterion-millet straw aminopherase (AST) and alanine aminotransferase (ALT) of organisms suffering from nonalcoholic fatty liver, and besides, can improve insulin resistance. Blood biochemistry detection indicates that the formononetin can also reduce the level of triglyceride (TG), cholesterol (TC) and low intensity lipoprotein (LDL-C) of HFD mice, and can improve the lipid disorders. The formononetin has important effects on treatment of nonalcoholic fattyliver.